G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after ...

Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...

Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for ...

Ledneczki I; Tapolcsányi P; Gábor E; Visegrády A; Vass M; Éles J; Holm P; Horváth A; Pocsai A; Mahó S; Greiner I; Krámos B; Béni Z; Kóti J; Káncz AE; Thán ...

Presented a poster highlighting the use of the Company’s Magellan™ drug discovery platform to identify allosteric inhibitors targeting discoidin domain receptor 2 at the 36 th EORTC-NCI-AACR Symposium ...

Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...

Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...